Analyses of Nivolumab Exposure and Clinical Safety Between 3-mg/kg Dosing and 240-mg Flat Dosing in Asian Patients with Advanced Renal Cell Carcinoma in the Real-World Clinical Setting

We aimed to identify the clinical characteristics related to increased nivolumab exposure in Japanese patients with renal cell carcinoma (RCC) in real-world clinical setting. Eleven patients were treated with the originally approved nivolumab dosing regimen of 3 mg/kg every 2 weeks (Q2W) (3-mg/kg gr...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Transl Oncol
Autores principales: Kato, Renpei, Ikarashi, Daiki, Matsuura, Tomohiko, Maekawa, Shigekatsu, Kato, Yoichiro, Kanehira, Mitsugu, Takata, Ryo, Tokuyama, Rie, Tamai, Kanako, Harigai, Naoto, Nakazaki, Yukoh, Obara, Wataru
Formato: Artigo
Lenguaje:Inglês
Publicado: Neoplasia Press 2020
Materias:
Original article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC7205763/
https://ncbi.nlm.nih.gov/pubmed/32375081
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.tranon.2020.100771
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares